OSCR
Oscar Health, Inc.
OSCR has the edge over RIGL overall, supported by stronger fundamentals and stronger modeled upside.
RIGL
Rigel Pharmaceuticals, Inc.
RIGL offers stronger valuation, but that advantage does not outweigh its weaker overall profile.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
RIGL Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Strong | |
| Strong | |
| Strong |
RIGL's profitability, cash flow and balance sheet are currently strong, but its revenue is under pressure.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over RIGL in the historical PE scenario, which offers more potential upside but is not a forecast.
RIGL PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 2x | $31.38 | -31% |
| Current | 2.8x | $45.69 | — |
| Fair | 6.3x | $102 | +122% |
| Forward | 13x | $45.69 | — |
| Expensive | 20x | $329 | +620% |
Historical ranges are pointers, not guarantees.
RIGL's PE is in its cheap range at 2.8x. On analysts' estimates for next year's earnings, today's price would be 13x, in its expensive range.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over RIGL on the outlook, with more favorable valuation and profitability expectations.
RIGL Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Strong growth | |
| Strong growth | |
| Strongly weakening | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for RIGL, but weaker profitability.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
RIGL Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $3.54 | -78% |
| Q3 2026 | $16.08 | +159% |
| Q2 2026 | $16.89 | +209% |
| Q1 2026 | $19.29 | +810% |
| Q4 2025 | $19.48 | +1868% |
| Q3 2025 | $6.22 | +2492% |
| Q2 2025 | $5.46 | +$6.22 |
| Q1 2025 | $2.12 | +$3.22 |
| Q4 2024 | $0.99 | +$2.39 |
RIGL has the edge over OSCR on earnings, with more consistent year-over-year improvement.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over RIGL on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
RIGL Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $80.9M | +16% |
| Q2 2026 | $78.7M | -23% |
| Q1 2026 | $58.8M | +10% |
| Q4 2025 | $69.8M | +21% |
| Q3 2025 | $69.5M | +26% |
| Q2 2025 | $101.7M | +176% |
| Q1 2025 | $53.3M | +81% |
| Q4 2024 | $57.6M | +61% |
RIGL's revenue is recovering but still below its 2025 peak: $81M last quarter, up 16% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 21% | -20 points |
| Q2 2026 | 30% | -30 points |
| Q1 2026 | 20% | -3.7 points |
| Q4 2025 | 33% | +4.3 points |
| Q3 2025 | 41% | +16 points |
| Q2 2025 | 60% | +59 points |
| Q1 2025 | 24% | +48 points |
| Q4 2024 | 29% | +23 points |
RIGL has the edge over OSCR on profitability, with a higher operating margin.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR usually generates cash, though not every quarter: the latest was −$1.2B, but it generated $4.1B over the past year.
RIGL Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $34.6M | +44% |
| Q2 2026 | $30.7M | +0.4% |
| Q1 2026 | $2.7M | +$3.6M |
| Q4 2025 | $22M | +52% |
| Q3 2025 | $24M | +11% |
| Q2 2025 | $30.5M | +10012% |
| Q1 2025 | -$893K | +$4.1M |
| Q4 2022 | -$22M | -$2.9M |
RIGL has the edge over OSCR on cash flow, with more consistent year-over-year improvement.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
RIGL Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +4.4% | +869K shares |
| 1 year | +6.7% | +1.3M shares |
| 3 years | +17% | +3M shares |
| 5 years | +20% | +3.4M shares |
| Available history | +22% | +3.7M shares |
RIGL has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $1M |
| Q2 2026 | $511,000 |
| Q1 2026 | $3.7M |
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over RIGL on leverage, with a lower net debt burden relative to earnings.
RIGL Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.6x | Net Cash |
| Q2 2026 | -0.7x | Net Cash |
| Q1 2026 | 0.2x | Very low |
| Q4 2025 | 0.1x | Very low |
| Q3 2025 | 0.1x | Very low |
| Q2 2025 | 0.1x | Very low |
| Q1 2025 | 0.3x | Very low |
| Q4 2024 | 0.1x | Very low |
RIGL has more cash than debt.
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
RIGL Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 54.3 | Neutral |
| Stochastic | 55.3 | Neutral |
RIGL's weekly RSI is 54 (neutral) and its Stochastic is 55 (neutral).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
RIGL PE vs Healthcare Sector
| Metric | RIGL | Sector median | Relative |
|---|---|---|---|
| PE | 2.8x | 26x | 89% below |
| PE % | 30 | 29 | 1 pt above |
RIGL has the edge over OSCR on valuation relative to its sector.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over RIGL on trend strength, trading above more of its moving averages.
RIGL Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $46.9 | 2.6% below |
| 20 week MA | $44.4 | 2.9% above |
| 50 week MA | $38.0 | 20% above |
| 100 week MA | $31.6 | 45% above |
| 200 week MA | $22.4 | 104% above |
RIGL's trend is up, with a small recent dip: it's below only its 8-week average, and 104% above its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over RIGL on returns for 2026, with the stronger performance.
RIGL Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $20.8 | $36.9 | +77% |
| 2021 | $36.9 | $28.4 | -23% |
| 2022 | $28.4 | $12.3 | -57% |
| 2023 | $12.3 | $14.5 | +18% |
| 2024 | $14.5 | $16.5 | +14% |
| 2025 | $16.5 | $44.0 | +167% |
| 2026 YTD | $44.0 | $45.7 | +3.8% |
RIGL's yearly returns have swung widely, from +167% in 2025 to −57% in 2022. It's up 3.8% so far in 2026.